Thermo Fisher Scientific

Pharma and biotech grew high single digits in Q4 and mid single digits for the full year, led by bioproduction, research and safety channel, and clinical research stepping up to mid-single-digit growth.

Announced definitive agreement to acquire Clario for approximately $9 billion, a market leader in digital endpoint data solutions generating approximately $1.5 billion revenue, expected to be accretive to adjusted EPS by approximately $0.45 in the first twelve months of ownership.

Initiated 2026 guidance with revenue of $46.3-$47.2 billion representing 3-4% organic growth, and adjusted EPS of $24.22-$24.80 representing 6-8% growth, consistent with prior midterm framework.

CFO Stephen Williamson retiring in March 2026 after 25 years and 10 years as CFO, with Jim Meyer promoted as successor after 17 years at the company.